NIH R01 · 2025
PROJECT SUMMARY Over 1 million people have type 1 diabetes in the United States and greatly affects their quality of life. In vivo measurement of insulin vesicle functional capacity (IVFC) and beta cell mass (BCM) would allow tracking and monitoring of recent advances in therapies designed to preserve IVFC and BCM and/or monitor transplanted beta cells. Beta cell loss occurs in the endocrine pancreas resulting in loss of insulin secretion and subsequent onset of diabetes. Current clinical measurements of beta cell function (e.g., C-peptide release in response to oral glucose tolerance test (OGTT)) may underrepresent total IFVC or BCM due to variability in beta cell function in response to…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.